Skip to main content
. Author manuscript; available in PMC: 2018 Jul 20.
Published in final edited form as: Nat Rev Clin Oncol. 2016 Mar 8;13(8):516–524. doi: 10.1038/nrclinonc.2016.30

Table 1.

Selected examples of published studies of SABR and Immunotherapy combinations

Study details SABR dose (Gy)/fractions SABR Target Immunotherapy agent Sequence of treatments Location of response
Postow et al., (2012)36 28.5/3 Paraspinal Ipilimumab immunotherapy, then SABR, then immunotherapy IF and OF
Hiniker et al., (2012)38 54/3 Liver Ipilimumab immunotherapy, then SABR, then immunotherapy IF and OF
Golden et al., (2013)39 30/5 Liver Ipilimumab Concurrent IF and OF
Silk et al., (2013)40 14–24/1–5 Brain Ipilimumab immunotherapy then SABR, or SABR then immunotherapy IF
Stamell et al., (2014)41 NR Brain Ipilimumab Concurrent IF and OF
Karbach et al., (2014)42 45/1 Brain Autologous tumor-lysate-loaded dendritic cells SABR then immunotherapy IF and OF
Kiess et al., (2014)43 15–24/1 Brain Ipilimumab SABR then immunotherapy, or Concurrent treatment, or Immunotherapy then SABR IF
Kwon et al., (2015)44 8/1 Bone Ipilimumab SABR then immunotherapy IF
Seung et al., (2012)45 20/1 Any IL-2 SABR then immunotherapy IF and OF

SABR, stereotactic ablative radiotherapy; IF, in field; OF, out of field.